Sun Pharma's $11.8 Billion Organon Acquisition Drives Stock Surge

By EC Assets · Published 27 April 2026 · Updated 28 May 2026

Sun Pharma has agreed to acquire U.S.-listed Organon in a deal valued at $11.75 billion. This transaction marks India's largest pharmaceutical acquisition. Following the announcement, Organon's stock price saw a significant increase. The acquisition price to be $11.75 billion. Another source indicates a value of $11.8 billion or $12 billion. mentions a sweetened offer of $13 billion. Sun Pharma's shares rose 7% immediately aer the news of the deal. Organon's stock surged by 15% and 31% reports. This acquisition highlights the growing interest of Indian pharmaceutical companies in expanding their global presence. The deal represents a significant strategic move for Sun Pharma into the U.S. market. It also reflects a trend of consolidation within the global pharmaceutical industry. Market participants will monitor the regulatory approval process for the acquisition. Any further statements from Sun Pharma or Organon regarding the deal’s progression will also be closely watched. This article is intended for informational purposes only. It does not constitute investment advice.